Use of a compound that inhibits interleukin-1beta converting enzyme (ICE/caspase-1) for the manufacture of a medicament for treating a disease or condition selected from reducing the duration of a seizure, reducing susceptibility of seizure onset, delaying seizure onset, or eliminating the occurrence of a seizure in a patient, wherein said compound is represented by the structural formulae depicted herein.
